Straight out yesterday’s press release from Valeant Pharmaceuticals:
Valeant Pharmaceuticals International (NYSE:VRX) today announced that the U.S. Food and Drug Administration (FDA) has given marketing approval for Cesamet (CII) (nabilone) oral capsules. Cesametis used to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatments.
“There is still a significant unmet need in treating one of the most feared and severe consequences of life-saving cancer therapies,” said Timothy C. Tyson, Valeant’s president and chief executive officer. “With the approval of Cesamet, Valeant is proud to offer a solution that will help alleviate one of the most common side effects of chemotherapy.”
Hat tip to The Drug Update and Drug War Rant. Drug War Rant adds “excuse me while I go bang my head against a wall,” by which I take him to mean that it is truly bizarre to see approval being issued for new drugs based on chemical analogues to marijuana less than a month after the FDA denied that (smoked) marijuana has any medical value.
